Isotechnika Inc.

Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an  agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting  Lux Biosciences worldwide rights to develop and commercialize Isotechnika's  lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases.

    ISA247 is a novel calcineurin inhibitor currently being investigated in  a Phase III trial for the treatment of moderate to severe psoriasis and a  Phase IIb trial for the prevention of organ rejection following  transplantation.

    Under the terms of the agreement:

@@start.t1@@            -  Lux Biosciences, Inc. will make upfront and milestone payments to
                 Isotechnika. Assuming all development milestones are achieved, the
                 amount of this deal will be $32,700,000 USD with Isotechnika
                 receiving an upfront payment of $3 million USD.
            -  Lux Biosciences, Inc. will pay Isotechnika royalties based on a
                 percentage of net sales.
            -  Lux Biosciences, Inc. has exclusive worldwide marketing rights of
                 ISA247 for all ophthalmic indications.
            -  Lux Biosciences, Inc. would be responsible, at its sole expense,
                 for pre-clinical and clinical development, registration, and
                 marketing of ISA247 for all ophthalmic indications.
            -  Isotechnika will be providing input on clinical trial design and
                 will be reviewing and consulting on all regulatory filings.
            -  A Joint Steering Committee ("JSC") with equal membership from
                 Isotechnika and Lux Biosciences, Inc. will be formed to oversee
                 the development and commercialization of all ophthalmic
                 indications.@@end@@

    "This agreement reconfirms the versatility of ISA247 as a multi- platform technology," stated Dr. Randall Yatscoff, Isotechnika's President  and Chief Executive Officer. "Lux Biosciences' team has extensive  experience in this area and we are extremely pleased to have them as a  partner. We believe this agreement provides us with another opportunity to  optimize shareholder value."

    Dr. Ulrich Grau, Lux Biosciences' President and CEO comments, "We are  delighted to be able to partner ISA247 for ophthalmic indications, and I  commend Isotechnika for its great efforts behind its flagship molecule. We  are highly impressed with the emerging profile of ISA247 that combines  efficacy with superior safety. We believe that ISA247 has the potential to  become the calcineurin inhibitor of choice with great potential in several  indications, including ophthalmic indications."

    Dr. Randall Yatscoff will chair a web cast this morning to provide an  overview of the agreement. The web cast will take place at 9:00 a.m. ET/ 7: 00 a.m. MT. All interested parties can access the live web cast (listen  only mode) by accessing http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID(equal sign)1497760  or through the home page of the Company's corporate Web site at  www.isotechnika.com.

    About Isotechnika Inc.

    ----------------------

    Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in  medicinal chemistry and immunology, the Company is focused on the discovery  and development of novel immunosuppressive therapeutics that are safer than  currently available treatments. Its entrepreneurial management and world- class team of scientists are building a pipeline of immunosuppressive drug  candidates for treatment of autoimmune diseases and for use in the  prevention of organ rejection in transplantation. Isotechnika looks to  become the leader in development of immunosuppressant therapies.

    Isotechnika's lead compound, ISA247 is an immunosuppressant currently  in an extension protocol of a Canadian Phase III human clinical trial for  the treatment of moderate to severe psoriasis. In addition, ISA247 has  successfully completed a Phase IIa trial for kidney transplantation. The  Company also has an additional immunosuppressive compound in its drug  pipeline, TAFA93 which is in Phase I.

    Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found  at www.isotechnika.com.

    About Lux Biosciences Inc.

    --------------------------

    Founded in 2005, Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and  commercialization of products for the treatment of ophthalmic diseases. The  company has assembled a portfolio of product candidates based on compounds  with demonstrated utility in non-ophthalmic indications that offer  potential to address major market opportunities in the ophthalmic field.  ISA247, the most advanced of these, is expected to enter pivotal clinical  trials for the treatment of uveitis by early 2007 and additionally offers a pipeline of other potential product applications. More information on Lux  Biosciences can be found at www.luxbio.com .

    Forward-Looking Statements

    --------------------------

    This press release may contain forward-looking statements. Forward-  looking statements, including the Company's belief as to the potential of  its products, the Company's expectations regarding the issuance of  additional patents and the Company's ability to protect its intellectual  property, involve known and unknown risks and uncertainties, which could  cause the Company's actual results to differ materially from those in the  forward- looking statements. Such risks and uncertainties include, among  others, the availability of funds and resources to pursue research and  development projects, the ability to economically manufacture its products,  the potential of its products, the success and timely completion of  clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's  patents may be subsequently shown to be invalid or infringe the patents of  others. Investors should consult the Company's quarterly and annual filings  with the Canadian commissions for additional information on risks and  uncertainties relating to the forward- looking statements. Investors are  cautioned against placing undue reliance on forward-looking statements.

    Archived images on this organization are searchable through CNW Photo  Archive website at http://photos.newswire.ca. Images are free to accredited  members of the media. To request a free copy of this organization's annual  report, please go to http://www.newswire.ca and click on Tools for Investors.

    Trades on Toronto Stock Exchange - (TSX:ISA)

    www.isotechnika.com

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
For further information: For Isotechnika: Dr. Randall Yatscoff,
President & CEO, Isotechnika Inc., Phone: +1-(780)487-1600 ext. 246,
Fax: +1(780)-484-4105, E-mail: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1(780)909- 4661, Fax: +1(780)-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com; For Lux Biosciences: Ulrich Grau,
Ph.D., President and CEO, Lux Biosciences, Inc., Phone
+1-(917)518-2875, E-mail: ulrich.grau@luxbio.com; Joan Kureczka ,
Kureczka/Martin Associates, Phone: +1(415)-821-2413, E-
mail:jkureczka@comcast.net; Archived images on this organization are
searchable through CNW Photo Archive website at
http://photos.newswire.ca. Images are free to accredited members of
the media. To request a free copy of this organization's annual
report, please go to http://www.newswire.ca and click on Tools for
Investors.



Weitere Meldungen: Isotechnika Inc.

Das könnte Sie auch interessieren: